~~<i id='B723007C71'><strike id='B723007C71'><tt id='B723007C71'><pre id='B723007C71'></pre></tt></strike></i>~~

Home» Wikipedia» comprehensive

comprehensive

author：fashion 2025-10-02 16:30:14 Page View：3697

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Venture capitalist Bob Kocher on the state of digital health
Next article： Continuity nursing helped my family in our darkest PICU moments

explore

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

The haunting brain science of long Covid

AdobeMattFitzgeraldusedtobikeupanddown3,500feetthroughtheSantaAnaMountainsonthree-hourridesjustforfu

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Addiction experts warn against a second 'war on drugs'

STAT'sLevFacher(left)spokewiththreeaddictionexperts—(fromleft)BraunzCourtney,KeithHumphreys,andAyesh